CMIC CMO Co., Ltd.

Medical device contract manufacturer Arterex (incorporated as Medical Devices Inc.) today said it has a deal to buy NextPhase Medical Devices. London-based private equity firm Investindustrial launched Arterex last year after combining Formula Plastics, Kabo, Luc & Bel and ModenPlast. Investindustrial said at the time that the combined company had more than 800 employees, four manufacturing sites and annual sales of around 100 million euros. NextPhase is a contract manufacturer of Class II and Class III complex electromechanical devices, active implantable devices and single-use disposables, Investindustrial said. NextPhase offers services spanning design and engineering, manufacturing and assembly, quality and regulatory, and supply chain and logistics management services for low-to-medium-volume devices. Investindustrial did not disclose terms of the latest deal, which is subject to customary approvals. But NextPhase will double the size of Arterex and bring its manufacturing facility count to seven in the U.S., Mexico, Italy and Egypt, the private equity firm said, with 70% of the combined company’s revenue coming from the U.S. Arterex Chair Charles Stroupe said NextPhase “adds measurably to the Arterex multi-capability business strategy to better serve and grow our customer base” and is “well positioned for growth.” “This acquisition is transformational and provides highly complementary manufacturing and assembly capabilities to the Arterex platform,” Stroupe said in a news release. “With the resulting capability diversification, this transaction will allow us to create significant synergies and enable us to better service our combined core blue-chip medical OEM customer base and regional specialty customers. Our combined platform will also have substantial production capabilities with a significantly diverse customer base across North America and Europe, well-positioned to continue our global growth strategy.” Investindustrial said Arterex was its first investment from its 1.1 billion euro Investindustrial Growth III fund.

MUNICH, BOSTON, and STANFORD, Calif., Nov. 30, 2022 /PRNewswire/ -- With AI becoming an integral part of clinical radiology workflows, the data used to develop AI algorithms is ever essential. An identified industry challenge is ensuring post-market surveillance of AI at scale, providing a foundation for the continued clinical safety and improvement of algorithms before and after clinical deployment. AI algorithms already need to meet high-performance standards for clearance by notified bodies such as the FDA. Continue Reading Dr. Martin Willemink, MD PhD, CEO Segmed, John Moulden, CCO deepc, Dr. Anna Tidstam, CTO, deepc, and Erik Duhaime, CEO Centaur Labs. (PRNewsfoto/Deepc) However, in some clinical scenarios, the performance of an AI algorithm may not meet expectations or degrade over time, e.g. due to different target patient populations or new scanner types. To identify such effects immediately, it is crucial to assess the performance of AI before and during its deployment in routine clinical use. In such cases, AI algorithms can then be re-trained on broader datasets, reflecting the target population, and making them more robust and safe. To address this need, deepc, Centaur Labs, and Segmed have joined forces and started a Radiology AI Safety Initiative to strengthen the continued AI performance in clinical workflows. Three leaders in the field of Radiology AI have formed a novel AI Safety initiative to make AI algorithm use in clinical routines safer, as well as management and retraining easier. MedTech company deepc with its leading radiology AI platform deepcOS offers radiologists access to a myriad of regulatory-cleared AI solutions from their globally leading partner network. Segmed provides secured, de-identified medical data, and Centaur Labs a labeling solution for such data.Collaborating with its AI Partners, deepc helps AI applications fulfill the highest safety and performance standards. Customers that use deepcOS commonly seek validation and benchmarking assistance to identify the optimal performance of algorithms and pre-launch safety checks, offering surety of selection meeting the specific needs of the clinical environment. Segmed's self-serve data platform Insight allows AI developers to build cohorts of de-identified and structured data that are readily available for training, testing, and validation of AI algorithms. Together with Centaur Labs, medical labeling services can be provided for given clinical indication fields to ensure safe operations of AI engines on specific customer data prior to deployment. The companies are developing a joint offering. AI vendors will be able to perform real-time post-market surveillance via the deepcOS platform and identify when an AI model is performing suboptimally over time, a phenomenon that is often regarded as 'AI drift'. This may be caused by a shifting patient population or new scanner types, for instance. deepc will avail this precise information to AI vendor partners and offer on-demand access to data that is anonymized and cleared for AI R&D through Segmed's data platform, and annotated by Centaur Lab's scalable data annotation platform. This data can be used to retrain the AI algorithm, improve performance, robustness, and clinical AI safety. Obtaining diverse, relevant data and labeling this data are two of the biggest bottlenecks in AI pipelines, solved by deepc's partners Segmed and Centaur Labs. "An outstanding effort of our companies leads to improved clinical AI safety, eventually leading to better clinical outcomes and increased patient safety. We are very proud to be leading this very important initiative in the industry", says deepc's Co-Founder and CEO Dr. Franz Pfister. Find more insights here: Photo - Press contact: Natalie Erdmann CMO [email protected] LinkedIn/company/deepchealth SOURCE Deepc

Leading compliance solutions provider will broaden company's capabilities across life sciences and create a robust platform for future innovation and growth CHICAGO, Oct. 17, 2022 /PRNewswire/ -- RLDatix, the leading global provider of healthcare operations software and services that drive safer care, announced today that it has entered into a definitive agreement to acquire Porzio Life Sciences, a market leader in compliance solutions for the life sciences industry which had been a wholly-owned subsidiary of the law firm of Porzio, Bromberg & Newman since 2004. Porzio Life Sciences simplifies compliance by combining its regulatory expertise with product innovation to deliver a truly unique solution to its customers. Designed by experienced lawyers and regulatory experts, Porzio Life Sciences is a database and software solutions business that automates transparency reporting and other compliance tasks for organizations around the world. Combined with RLDatix's existing governance, risk, compliance (GRC) and workforce management offerings, Porzio Life Sciences broadens the company's capabilities across life sciences and provides a comprehensive set of tools at global scale. "RLDatix's acquisition of Porzio Life Sciences, when combined with our current solutions, will create a comprehensive suite of compliance offerings for the life sciences industry and a global leader in governance, risk, compliance and workforce management," said Jeff Surges, CEO, RLDatix. "We're excited to bring these capabilities together and to forge an innovative new path forward for our hundreds of pharmaceutical, biotech and medical device clients around the world." Porzio, Bromberg & Newman will continue to maintain a strategic relationship with the company after the transaction closes. The two entities will co-market Porzio Life Sciences' products and services and will collaborate to deliver innovative compliance solutions for the life sciences industry. "This is a great day for our clients," said Vito A. Gagliardi, Jr., Managing Principal, Porzio, Bromberg & Newman. "Under RLDatix's leadership, Porzio Life Sciences will continue to simplify the compliance efforts of pharmaceutical companies while benefiting from the global scale and reach that is critical to driving ongoing success and growth." John Oroho, the Porzio, Bromberg & Newman lawyer who founded and developed Porzio Life Sciences, will join RLDatix as President and General Manager of RLDatix's life sciences division. "The success of Porzio Life Sciences was always predicated on the notion of being built from the law," said Oroho. "As we join forces with RLDatix, I am inspired by their commitment to putting the voice of the customer at the forefront of everything they do. Together, we will deliver innovative solutions that exceed the expectations of our clients." The transaction is scheduled to close early next month subject to customary closing conditions which are expected to be completed in the coming weeks. About RLDatix RLDatix is a global healthcare technology company helping organizations to provide safer care. Trusted by over 6,000 customers, we integrate and automate workflows across governance, risk, compliance (GRC), and workforce management functions to deliver critical insights that improve quality outcomes. As the only technology platform linking workforce management and GRC, our broad suite of enterprise software applications and services enable the identification of risk, enhance operational efficiency and compliance, and build a consistent, transparent culture of safety. RLDatix is committed to helping our customers inspire trust and provide a better, safer experience for clinicians, staff, and patients alike. RLDatix is controlled by Five Arrows, TA Associates and Nordic Capital as major shareholders. Visit rldatix.com to learn more. About Porzio Life Sciences Porzio Life Sciences provides compliance services and solutions to the life sciences industry. Porzio Life Sciences' Global Risk Management Platform features software solutions and services that are "built from the law" by a team of regulatory compliance experts. The company's comprehensive solutions help inhouse compliance and legal professionals manage all aspects of the compliance lifecycle including; regulatory research, spend transparency reporting, monitoring and analytics, price transparency, and management and tracking of high-risk engagements in jurisdictions around the country and the world— all with world-class support from dedicated regulatory experts. About Porzio, Bromberg & Newman Porzio, Bromberg & Newman, P.C. is a full-service law firm headquartered in Morristown, New Jersey. Founded in 1962, the firm has over 90 lawyers located in 8 offices throughout New Jersey, New York, Delaware, Massachusetts, Pennsylvania, and Puerto Rico. For More Information: Mike Etzinger CMO, North America RLDatix [email protected] SOURCE RLDatix